(0.98%) 5 113.93 points
(1.09%) 38 644 points
(1.71%) 16 113 points
(-0.30%) $78.71
(0.34%) $2.04
(-0.37%) $2 301.00
(-0.83%) $26.61
(0.29%) $965.40
(-0.36%) $0.929
(-1.26%) $10.85
(-0.13%) $0.797
(0.21%) $91.32
0.00% $ 8.75
Live Chart Being Loaded With Signals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies...
Stats | |
---|---|
Volumen de hoy | 108 700 |
Volumen promedio | 377 429 |
Capitalización de mercado | 260.61M |
EPS | $0 ( 2024-04-01 ) |
Próxima fecha de ganancias | ( $-0.420 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.12 |
ATR14 | $0.0360 (0.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Nicholson, C. David | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | Steinhart Richard I | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | O'loughlin Steve | Buy | 253 123 | Stock Option (Right to Buy) |
2023-12-28 | Shetty Ajit | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | Seth Sandesh | Buy | 984 367 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 13 159 883 | Sell: 1 707 212 |
Volumen Correlación
Actinium Pharmaceuticals Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Actinium Pharmaceuticals Correlación - Moneda/Commodity
Actinium Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $81 000.00 |
Beneficio Bruto: | $-709 000 (-875.31 %) |
EPS: | $-1.830 |
FY | 2023 |
Ingresos: | $81 000.00 |
Beneficio Bruto: | $-709 000 (-875.31 %) |
EPS: | $-1.830 |
FY | 2022 |
Ingresos: | $1.03M |
Beneficio Bruto: | $331 000 (32.14 %) |
EPS: | $-1.320 |
FY | 2021 |
Ingresos: | $1.14M |
Beneficio Bruto: | $1.14M (100.00 %) |
EPS: | $-2.17 |
Financial Reports:
No articles found.
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico